A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.

@article{Sutter2008ALA,
  title={A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.},
  author={Jennifer A Sutter and Jennifer Kwan-Morley and Jon Dunham and Y. Du and Malek Kamoun and Daniel Albert and Robert A. Eisenberg and Eline T Luning Prak},
  journal={Clinical immunology},
  year={2008},
  volume={126 3},
  pages={282-90}
}
Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis… CONTINUE READING